Zealand Pharma has filed a patent for compounds that act as a4ß7 antagonists, which can be used to prevent or treat inflammatory conditions and autoimmune diseases, particularly inflammatory bowel disease. The patent claims a compound of a specific formula, including its stereochemistry. GlobalData’s report on Zealand Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Zealand Pharma AS - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Zealand Pharma, Hormone-based therapies for metabolic disorders was a key innovation area identified from patents. Zealand Pharma's grant share as of September 2023 was 38%. Grant share is based on the ratio of number of grants to total number of patents.

The patent is filed for a4ß7 antagonists for inflammatory conditions

Source: United States Patent and Trademark Office (USPTO). Credit: Zealand Pharma AS

A recently filed patent (Publication Number: US20230295235A1) describes a compound and its pharmaceutical applications. The compound, represented by formula (I), or its pharmaceutically acceptable salt or solvate, is the subject of the patent. The stereochemistry of the carbon atom at each of positions 1a, 1b, 2a, 2b, 3a, 3b, 4a, 4b, 5a, 5b, 6a, 6b, 7a, and 7b can be independently (R) or (S).

The patent claims specify various aspects of the compound and its applications. Claim 2 states that the stereochemistry of the carbon atom at positions 1a and 1b is (S). Similarly, claims 3, 4, 5, 6, 7, and 8 specify the stereochemistry of the carbon atoms at positions 2a, 2b, 3a, 3b, 4a, 4b, 5a, 5b, 6a, 6b, 7a, and 7b, respectively. Claim 8 specifically mentions that the stereochemistry at positions 7a and 7b is (R).

The patent also covers the use of the compound in pharmaceutical compositions. Claim 10 states that the compound, along with a pharmaceutically acceptable carrier, can be used to formulate a pharmaceutical composition. Furthermore, the patent describes methods of treating inflammation or autoimmune diseases, particularly gastrointestinal conditions. Claim 12 specifies the administration of the compound or its pharmaceutically acceptable salt or solvate to treat inflammation or autoimmune diseases in patients. Claim 13 further specifies that the inflammation or autoimmune disease can be gastrointestinal in nature.

Additionally, the patent covers the treatment of various conditions using the compound. Claim 14 describes the administration of the compound or its pharmaceutically acceptable salt or solvate to treat conditions such as Inflammatory Bowel Disease (IBD), ulcerative colitis, Crohn’s disease, celiac disease, and gastrointestinal cancer, among others. Claims 15, 16, and 17 specifically mention the treatment of IBD, ulcerative colitis, and Crohn’s disease, respectively.

Lastly, the patent includes a method of treating viral or retroviral infections in patients. Claim 18 specifies the administration of the compound or its pharmaceutically acceptable salt or solvate to treat local or systemic infections caused by viruses or retroviruses. Claim 19 specifically mentions the treatment of HIV infections.

In summary, the filed patent describes a compound and its pharmaceutical applications, including the treatment of inflammation, autoimmune diseases, gastrointestinal conditions, and viral infections. The patent claims cover the compound's stereochemistry and its use in pharmaceutical compositions for therapeutic purposes.

To know more about GlobalData’s detailed insights on Zealand Pharma, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies